• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    VP, Clinical Trial Operations Yu Yong was granted 13,350 shares, increasing direct ownership by 33% to 53,219 units (SEC Form 4)

    4/17/25 4:56:26 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Yu Yong

    (Last) (First) (Middle)
    C/O GENELUX CORPORATION
    2625 TOWNSGATE ROAD, SUITE 230

    (Street)
    WESTLAKE VILLAGE CA 91361

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GENELUX Corp [ GNLX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    VP, Clinical Trial Operations
    3. Date of Earliest Transaction (Month/Day/Year)
    03/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/14/2025 A(1) 13,350 A $0 53,219 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025.
    /s/ Sean Ryder, Esq., Attorney-in-Fact 04/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP, Clinical Trial Operations Yu Yong sold $16,291 worth of shares (5,579 units at $2.92), decreasing direct ownership by 10% to 47,640 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:37 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Pharmaceutical Development Cappello Joseph sold $13,832 worth of shares (4,737 units at $2.92), decreasing direct ownership by 8% to 52,266 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:36 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zindrick Thomas sold $31,431 worth of shares (10,764 units at $2.92), decreasing direct ownership by 5% to 191,447 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      5/13/25 5:05:39 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care